Regorafenib

Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.

Map view:

Zoom: 100%

More settings

Connection length 100% Label size 100% Node size 100% Line width 100% Label width 100%

Export map as:

Regorafenib topic overview

The analysis highlights Other actions, Approvals and indications and Adverse effects as prominent areas in the source structure around Regorafenib.

Related topics: 25
Source areas: 5
Connected nodes: 30
Extracted relationships: 62
Concept neighborhoods: 15
Bridge connections: 30

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Other actions · 9 topics

Approvals and indications · 7 topics

Adverse effects · 4 topics

Overview · 4 topics

Brand names · 1 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol): Interactive image
AHFS/Drugs.com: Monograph
ATC code: L01EX05 (WHO)
Bioavailability: 69-83%
CAS Number: 755037-03-7
ChEBI: CHEBI:68647

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Approvals and indications

Colorectal cancer
US FDA Food and Drug Administration
Cancer Drugs Fund
Gastrointestinal stromal tumors Gastrointestinal stromal tumor
National Institute for Health and Care Excellence
Hepatocellular carcinoma
Sorafenib

Adverse effects

Other actions

Soluble epoxide hydrolase
Epoxyeicosatrienoic acids Epoxyeicosatrienoic acid
Epoxydocosapentaenoic acids Epoxydocosapentaenoic acid
Epoxyeicosatetraenoic acids Epoxyeicosatetraenoic acid
Cytochrome P450
Epoxygenases Epoxygenase
DHA Docosahexaenoic acid
Preclinical studies
Omega-3 fatty acids

Brand names

Bangladesh

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How Regorafenib connects Entity context

The extracted context around Regorafenib shows recurring relationship patterns in the source. For example, Regorafenib → DHA, EDP, EDPs, EEQs, EETs, EPA, However, It, P450, These Another extracted example is Regorafenib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only. Use these groups to spot repeated connection types before inspecting the individual relationships.

Top relations

related to Other actions · 10

Regorafenib → DHA, EDP, EDPs, EEQs, EETs, EPA, However, It, P450, These

Legal status · 5

Regorafenib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only

related to Advanced hepatocellular carcinoma · 5

Regorafenib → Care Excellence, Health, In November, National Institute, NICE

related to Clinical trials · 5

Regorafenib → After, CONCUR, CONSIGN, CORRECT, MetastaticCRC

related to Advanced gastrointestinal stromal tumours · 4

Regorafenib → FDA-approved, In, In February, US FDA

related to Metastatic colorectal cancer · 4

Regorafenib → After, English Cancer Drugs Fund, September, US FDA

has effect · 3

Regorafenib → Boxed Warning, Serious, The

3D model (JSmol) · 1

Regorafenib → Interactive image

AHFS/Drugs.com · 1

Regorafenib → Monograph

ATC code · 1

Regorafenib → L01EX05 (WHO)

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

patients cancer advanced us effects stromal names approved treated tyrosine kinase liver clinical actions brand approvals name stivarga growth studies

Regorafenib relationships Subject–Predicate–Object triples

TTTA extracted 62 structured relationships around Regorafenib. Examples in this analysis include Regorafenib → 3D model (JSmol) → Interactive image and Regorafenib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.

Subject	Predicate	Object	Confidence	Src
Regorafenib	3D model (JSmol)	Interactive image	1.00	infobox
Regorafenib	AHFS/Drugs.com	Monograph	1.00	infobox
Regorafenib	ATC code	L01EX05 (WHO)	1.00	infobox
Regorafenib	Bioavailability	69-83%	1.00	infobox
Regorafenib	CAS Number	755037-03-7	1.00	infobox
Regorafenib	ChEBI	CHEBI:68647	1.00	infobox
Regorafenib	ChEMBL	ChEMBL1946170	1.00	infobox
Regorafenib	ChemSpider	9342697	1.00	infobox
Regorafenib	CompTox Dashboard (EPA)	DTXSID60226441	1.00	infobox
Regorafenib	DrugBank	DB08896	1.00	infobox
Regorafenib	ECHA InfoCard	100.248.939	1.00	infobox
Regorafenib	Elimination half-life	20-30 hours	1.00	infobox
Regorafenib	Excretion	Feces (71%), urine (19%)	1.00	infobox
Regorafenib	Formula	C21H15ClF4N4O3	1.00	infobox
Regorafenib	KEGG	D10138	1.00	infobox
Regorafenib	Legal status	AU: S4 (Prescription only)	1.00	infobox
Regorafenib	Legal status	CA: ℞-only	1.00	infobox
Regorafenib	Legal status	UK: POM (Prescription only)	1.00	infobox
Regorafenib	Legal status	US: ℞-only	1.00	infobox
Regorafenib	Legal status	EU: Rx-only	1.00	infobox
Regorafenib	License data	US DailyMed: Regorafenib	1.00	infobox
Regorafenib	MedlinePlus	a613004	1.00	infobox
Regorafenib	Metabolism	Liver (UGT1A9-mediated)	1.00	infobox
Regorafenib	Molar mass	482.82 g·mol−1	1.00	infobox
Regorafenib	Other names	BAY 73-4506	1.00	infobox
Regorafenib	Pregnancy category	AU: D	1.00	infobox
Regorafenib	Protein binding	99.5%	1.00	infobox
Regorafenib	PubChem CID	11167602	1.00	infobox
Regorafenib	Routes of administration	By mouth	1.00	infobox
Regorafenib	Trade names	Stivarga, Regonix	1.00	infobox

Related concept clusters Concept neighborhoods

The concept neighborhoods around Regorafenib bring nearby vocabulary together. In this analysis, examples include Treated, Patients and Clinical. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

Regorafenib
- Treated
- Patients
- Clinical
- Studies
- Approved
- Cancer
- Activity
- Brand
- Carcinoma
- Dha
- Hepatocellular
- Inhibition
regorafenib
- Treated
- Patients
- Clinical
- Studies
- Approved
- Cancer
- Activity
- Brand
- Carcinoma
- Dha
- Hepatocellular
- Inhibition
colorectal cancer
- Metastatic
- Carcinoma
- Gastrointestinal
- Hepatocellular
- Name
- Names
- Regonix
- Stivarga
- Trade
- Trials
- Growth
- Clinical
us fda
- Advanced
- Approvals
- Gastrointestinal
- Stromal
- Approved
- Colorectal
- Metastatic
- Patients
- Brand
- Carcinoma
- Hepatocellular
- Name
cancer drugs fund
- Growth
- Colorectal
- Metastatic
- Regorafenib
- Carcinoma
- Dha
- Gastrointestinal
- Hepatocellular
- Inhibition
- Name
- Names
- Regonix
gastrointestinal stromal tumors
- Gastrointestinal
- Stromal
- Us
- Approved
- Metastatic
- Advanced
- Carcinoma
- Colorectal
- Hepatocellular
- Name
- Names
- Patients
approvals and indications
- Us
- Advanced
- Colorectal
- Metastatic
- Brand
- Carcinoma
- Gastrointestinal
- Hepatocellular
- Name
- Names
- Regonix
- Stivarga
other actions
- Effects
- Colorectal
- Metastatic
- Approvals
- Brand
- Carcinoma
- Dha
- Gastrointestinal
- Hepatocellular
- Name
- Names
- Regonix

Connections between topic areas Semantic bridges

For Regorafenib, one of the stronger structural bridges in this analysis connects Regorafenib with Other actions. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3

Regorafenib — Other actions · splits 21 ⟂ 10

Regorafenib — Approvals and indications · splits 23 ⟂ 8

Regorafenib — Overview · splits 26 ⟂ 5

Regorafenib — Adverse effects · splits 26 ⟂ 5

Map overview Semantic statistics

Regorafenib

Nodes31

Edges30

Triples62

Avg. degree1.94

Density0.064516

Components1

Source & methodology

TTTA analyzes the structure around Regorafenib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Other actions, Approvals and indications & Adverse effects, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Regorafenib · EN edition · Analysis: TopicsToTalkAbout